Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

키워드

참고문헌 (57)

1. Peyrin-Biroulet L, "Surgery in a populationbased cohort of Crohn's disease from Olmsted County, Minnesota(1970-2004)", Am J Gastroenterol, 107, pp.1693~1701 (2012)
2. Vernier-Massouille G, "Natural history of pediatric Crohn's disease : a population-based cohort study", Gastroenterology, 135, pp.1106~1113 (2008)
3. Thia KT, "Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort", Gastroenterology, 139, pp.1147~1155 (2010)
4. Burisch J, "Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort : an Epi-IBD study", J Crohns Colitis, 13, pp.198~208 (2019)
5. Jenkinson PW, "Temporal trends in surgical resection rates and biologic prescribing in Crohn's disease : a population-based cohort study", J Crohns Colitis, 14, pp.1241~1247 (2020)
6. Olivera P, "Surgical rates in the era of biological therapy : up, down or unchanged?", Curr Opin Gastroenterol, 33, pp.246~253 (2017)
7. Turner D, "STRIDE-II : an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)initiative of the International Organization for the Study of IBD(IOIBD). Determining therapeutic goals for treat-to-target strategies in IBD", Gastroenterology, 160, pp.1570~1583 (2021)
8. Bouguen G, "Treat to target : a proposed new paradigm for the management of Crohn's disease", Clin Gastroenterol Hepatol, 13, pp.1042~1050 (2015)
9. Colombel JF, "Effect of tight control management on Crohn's disease(CALM) : a multicentre, randomised, controlled phase 3 trial", Lancet, 390, pp.2779~2789 (2017)
10. Feuerstein JD, "American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease", Gastroenterology, 153, pp.827~834 (2017)
11. Papamichael K, "Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 17, pp.1655~1668 (2019)
12. Shukla R, "Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics", Clin Gastroenterol Hepatol, 19, pp.1108~1110 (2021)
13. Kennedy NA, "Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease : a prospective, multicentre, cohort study", Lancet Gastroenterol Hepatol, 4, pp.341~353 (2019)
14. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
15. Adedokun OJ, "Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease", Gastroenterology, 154, pp.1660~1671 (2018)
16. Vande Casteele N, "American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases", Gastroenterology, 153, pp.835~857 (2017)
17. Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)
18. Seow CH, "Trough serum infliximab : a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis", Gut, 59, pp.49~54 (2010)
19. Maser EA, "Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease", Clin Gastroenterol Hepatol, 4, pp.1248~1254 (2006)
20. Adedokun OJ, "Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis", Gastroenterology, 147, pp.1296~1307 (2014)
21. Cornillie F, "Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab : a retrospective analysis of the ACCENT I trial", Gut, 63, pp.1721~1727 (2014)
22. Papamichael K, "Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD : evolution in the definition and management of primary nonresponse", Inflamm Bowel Dis, 21, pp.182~197 (2015)
23. 최소윤, "Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease", Gut and Liver, 13(5), pp.541~548 (2019), 거트앤리버 소화기연관학회협의회[DOI]
24. Vande Casteele N, "Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis", Clin Gastroenterol Hepatol, 17, pp.1814~1821 (2019)
25. Dreesen E, "Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease : pharmacokinetic-pharmacodynamic analysis of TAILORIX", J Crohn’s Colitis, 12(Suppl 1), pp.S063~S064 (2018)
26. Vande Casteele N, "Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease : a post-hoc analysis of the ACCENT-2 trial", J Crohn’s Colitis, 13(Suppl 1), pp.S053~S054 (2019)
27. Chiu YL, "Serum adalimumab concentration and clinical remission in patients with Crohn's disease", Inflamm Bowel Dis, 19, pp.1112~1122 (2013)
28. Roblin X, "Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 12, pp.80~84 (2014)
29. Ungar B, "Optimizing anti-TNF-αtherapy : serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 14, pp.550~557 (2016)
30. Colombel JF, "Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease", Clin Gastroenterol Hepatol, 12, pp.423~431 (2014)
31. Vande Casteele N, "Exposureresponse relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease", Aliment Pharmacol Ther, 47, pp.229~237 (2018)
32. Adedokun OJ, "Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis : results from Phase 2", 3 PURSUIT Induction and Maintenance Studies, 2017, pp.11, 35~46
33. Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn's disease", N Engl J Med, 369, pp.711~721 (2013)
34. Guidi L, "Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease", United European Gastroenterol J, 7, pp.1189~1197 (2019)
35. Dreesen E, "Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 16, pp.1937~1946 (2018)
36. Sandborn WJ, "Ustekinumab induction and maintenance therapy in refractory Crohn's disease", N Engl J Med, 367, pp.1519~1528 (2012)
37. Feagan BG, "Ustekinumab as induction and maintenance therapy for Crohn's disease", N Engl J Med, 375, pp.1946~1960 (2016)
38. Sands BE, "Ustekinumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 381, pp.1201~1214 (2019)
39. Verstockt B, "Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates", J Crohns Colitis, 13, pp.864~872 (2019)
40. van Rheenen PF, "The medical management of paediatric Crohn's disease : an ECCO-ESPGHAN guideline update", J Crohns Colitis, 15, pp.171~194 (2021)
41. Ben-Horin S, "Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 11, pp.444~447 (2013)
42. Sazonovs A, "HLADQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease", Gastroenterology, 158, pp.189~199 (2020)
43. Baert F, "Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy : a post hoc analysis of the Karmiris trial", Gut, 65, pp.1126~1131 (2016)
44. Bian S, "Antibodies toward vedolizumab appear from the first infusion onward and disappear over time", Inflamm Bowel Dis, 23, pp.2202~2208 (2017)
45. Chiu HY, "The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab", PLoS One, 10, pp.e0142930~ (2015)
46. Paul S, "Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease : a prospective study", Inflamm Bowel Dis, 19, pp.2568~2576 (2013)
47. Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
48. Yanai H, "Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab", Clin Gastroenterol Hepatol, 13, pp.522~530 (2015)
49. Steenholdt C, "Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment : a randomised, controlled trial", Gut, 63, pp.919~927 (2014)
50. Vaughn BP, "Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease : results from a pilot observational study", Inflamm Bowel Dis, 20, pp.1996~2003 (2014)
51. Papamichael K, "Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab", Clin Gastroenterol Hepatol, 15, pp.1580~1588 (2017)
52. Papamichael K, "Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease", J Crohns Colitis, 13, pp.976~981 (2019)
53. Vande Casteele N, "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease", Gastroenterology, 148, pp.1320~1329 (2015)
54. Assa A, "Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring", Gastroenterology, 157, pp.985~996 (2019)
55. Lamb CA, "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults", Gut, 68(Suppl 3), pp.s1~s106 (2019)
56. Mahadevan U, "Inflammatory bowel disease in pregnancy clinical care pathway : a report from the American Gastroenterological Association IBD Parenthood Project Working Group", Gastroenterology, 156, pp.1508~1524 (2019)
57. Sparrow MP, "Therapeutic drug monitoring of biologics during induction to prevent primary non-response", J Crohns Colitis, 14, pp.542~556 (2020)

관련 논문AI추천